ClinicalTrials.gg
TerminatedNCT01773785Updated Oct 13, 2021

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

A Phase 2 interventional study of SPI-1620 and Docetaxel in Biliary Cancer, sponsored by Spectrum Pharmaceuticals, Inc. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-13.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study completed the first phase and did not meet efficacy end point to enter into the randomized phase.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies in Biliary Tract Neoplasms with a site in United States — 48 open to participants now, 67 under way, 9 of them phase 3. Biliary Tract Neoplasms · United States.

Enrollment
111th of 140
30 · median 75
Started
2013
with 3 others
Phase 2
51 of 155
9 open now
Registered
27th of 155
by date

Among the 155 studies in Biliary Tract Neoplasms with a site in United States, this one is the 111th largest by enrollment of the 140 interventional ones that give a count, is one of 4 that started in 2013, is one of 51 in phase 2, and was the 27th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

48 of the 155 studies in Biliary Tract Neoplasms with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Biliary Tract Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.

03

Conditions studied

  • Biliary Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed biliary tract or gallbladder cancer that have or are refractory after one prior gemcitabine-based chemotherapy regimen for advanced biliary cancer
  • Evaluable disease
  • PS ≤ 2
  • Adequate bone marrow, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • Treatment with more than one prior chemotherapy regimen
  • Known, uncontrolled
  • Baseline peripheral neuropathy ≥ grade 2.
  • Significant circulatory disorders in the past 6 months
  • Concomitant use of phosphodiesterase inhibitors
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    SPI-1620 & Docetaxel

    Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.

    Drug: SPI-1620 · Drug: Docetaxel

Interventions

  • SPI-1620 11 μg/m2 will be given intravenously over 1 minute.

  • Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Time frame: 18 months

Secondary outcomes

  1. Overall response rate

    Time frame: 18 months

  2. Overall survival

    Time frame: 18 months

  3. Duration of Response

    Time frame: 12 months

  4. Safety of SPI-1620 when administered in combination with docetaxel

    Periodic physical examinations with vital sign monitoring, safety laboratories and monitoring of adverse events will be performed

    Time frame: 12 months

07

Study locations

6 sites
  • University of Miami Hospitals & Clinics/ Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Washington University School of Medicine
    Saint Louis, Missouri, United States
  • Associates in Oncology and Hematology
    Chattanooga, Tennessee 37421, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2013 to primary completion in Sep 2015, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2013
First posted
Jan 23, 2013
StartActual
Apr 2013
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results delay requested
Sep 30, 2021
Last update
Oct 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01773785
Responsible party
Sponsor
First posted
Jan 23, 2013
Start date
Apr 2013
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Oct 13, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovateltide

Start the discussion